natgillin/translations-raw huggingface dataset:
Not known*: Hypersensitivity**, manifested by isolated spontaneous reports including, but not limited to angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), pulmonary eosinophilia, vesicobullous rash with mucous membrane involvement and sensation of oropharyngeal swelling, anaphylaxis**, infusion reactions including the following symptoms: tachycardia, wheezing, pyrexia, rigors, systemic flushing, vertigo, syncope and metallic taste 
preobčutljivost**, razvidna iz posameznih spontanih poročil, vključno z, a ne omejeno na angioedem, z zdravilom povezani izpuščaj z eozinofilijo in sistemskimi simptomi (DRESS), pljučna eozinofilija, vezikulobulozni izpuščaj s prizadetostjo sluznic in občutek otekanja ust in žrela, anafilaksija**, infuzijske reakcije, ki vključujejo naslednje simptome: tahikardijo, piskajoče dihanje, pireksijo, okorelost, pordevanje po celem telesu, vrtoglavico, sinkopo in kovinski okus v ustih
12 mg/kg once every 
12 mg/kg vsakih
Based on these study results, both methods of daptomycin administration, the 2-minute intravenous injection and the 30-minute intravenous infusion, 
Glede na rezultate teh študij imata oba načina dajanja daptomicina, tako 2-minutna intravenska injekcija kot 30-minutna intravenska infuzija, podoben profil varnosti in prenašanja.
The response to treatment, renal function and creatine phosphokinase (CPK) levels should be closely monitored in all patients with any degree of renal impairment (see sections 4.4 and 5.2). 
Pri vseh bolnikih z okvaro ledvic katerekoli stopnje je treba natančno spremljati odziv na zdravljenje, delovanje ledvic in ravni kreatin-fosfokinaze (CPK - Creatine Phosphokinase) (glejte poglavji 4.4 in 5.2).
a 2-6 years (N=7) 
2-6 let (N = 7)
In paediatric patients aged 7 to 17 years, Daptomycin Hospira is given by intravenous infusion over a 30-minute period (see section 6.6). 
Pri pediatričnih bolnikih (starih od 7 do 17 let) se zdravilo Daptomycin Hospira daje v obliki intravenske infuzije s časom infundiranja 30 minut (glejte poglavje 6.6).
Invert the vial in order to allow the solution to drain towards the stopper. 
Obrnite vialo tako, da raztopina lahko steče proti zamašku.
If CDAD is suspected or confirmed, daptomycin may need to be discontinued and appropriate treatment instituted as clinically indicated. 
Če obstaja sum na CDAD ali so njeno diagnozo potrdili, je v skladu s klinično indikacijo morda treba prekiniti uporabo daptomicina in uvesti ustrezno zdravljenje.
In paediatric patients aged 1 to 6 years, Daptomycin Hospira is given by intravenous infusion over a 60-minute period (see section 6.6). 
Pri pediatričnih bolnikih (starih od 1 do 6 let) se zdravilo Daptomycin Hospira daje v obliki intravenske infuzije s časom infundiranja 60 minut (glejte poglavje 6.6).
The efficacy of daptomycin in patients with prosthetic valve infections or with left-sided infective endocarditis due to Staphylococcus aureus has not been demonstrated. 
Pri bolnikih z okužbo umetne zaklopke ali levostranskim infekcijskim endokarditisom zaradi bakterije Staphylococcus aureus učinkovitosti daptomicina niso dokazali.
The reconstituted and diluted solution should then be infused intravenously over 30 or 60 minutes. 
Rekonstituirano in razredčeno raztopino morate nato intravensko infundirati 30 ali 60 minut.
Paediatric patients (1 to 17 years of age) The recommended dosage regimens for paediatric patients based on age and indication are shown below. 
Spodaj so navedeni priporočeni režimi odmerjanja za pediatrične bolnike glede na starost in indikacijo.
The active substance in Daptomycin Hospira powder for solution for injection/infusion is daptomycin. 
Učinkovina v zdravilu Daptomicin Hospira prašek za raztopino za injiciranje/infundiranje je daptomicin.
Eosinophilic pneumonia has been reported in patients receiving daptomycin (see section 4.8). 
Pri bolnikih, ki so prejemali daptomicin, so poročali o eozinofilni pljučnici (glejte poglavje 4.8).
- CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy. 
• Pri bolnikih, pri katerih obstaja večje tveganje za nastanek miopatij, je treba CPK meriti pogosteje (na primer vsaka 2-3 dni, vsaj v prvih dveh tednih zdravljenja).
Uncommon: Myositis, increased myoglobin, muscular weakness, muscle pain, arthralgia, serum lactate dehydrogenase (LDH) increased, muscle cramps 
miozitis, zvišane vrednosti mioglobina, mišična oslabelost, bolečine v mišicah, artralgija, zvišane vrednosti laktatdehidrogenaze (LDH) v serumu, mišični krči rabdomioliza neznana pogostnost *:
Available in packs containing 1 vial or 5 vials. 
Zdravilo je na voljo v pakiranjih po 1 ali 5 vial.
See below for dose adjustments in patients with renal impairment. 
Za prilagajanje odmerkov pri bolnikih z okvaro ledvic glejte spodaj.
After a single 4 mg/kg dose of daptomycin, total clearance of daptomycin in children 7-11 years of age with Gram-positive infection was higher than in adolescents, whereas elimination half-life was shorter. 
Po enkratnem odmerku 4 mg/kg daptomicina je bil celotni očistek daptomicina pri otrocih, v starosti od 7 do 11 let, z grampozitivnimi okužbami večji kot pri mladostnikih, eliminacijski razpolovni čas pa je bil krajši.
- New or worsening fever, cough or difficulty breathing. 
- zvišana telesna temperatura, kašelj ali težko dihanje oziroma poslabšanje teh simptomov.
In a single human case study, daptomycin was intravenously administered daily for 28 days to a nursing mother at a dose of 500 mg/day, and samples of the patient's breast milk were collected over a 24-hour period on day 27. 
V študiji enega samega primera pri ljudeh je doječa mati 28 dni enkrat na dan prejemala daptomicin v intravenskem odmerku 500 mg/dan.
Daptomycin was not mutagenic or clastogenic in a battery of in vivo and in vitro genotoxicity tests. 
Daptomicin v seriji preskušanj genotoksičnosti in vivo in in vitro ni bil mutagen ali klastogen.
To prepare Daptomycin Hospira for intravenous injection, please adhere to the following instructions: Aseptic technique should be used throughout to reconstitute lyophilised Daptomycin Hospira. 
Pri pripravi zdravila Daptomicin Hospira za intravensko injekcijo upoštevajte naslednja navodila: Za rekonstitucijo liofiliziranega zdravila Daptomicin Hospira morate ves čas uporabljati aseptično tehniko.
Unlike in adults, daptomycin should not be administered by injection over a 2-minute period in paediatric patients. 
V nasprotju z odraslimi bolniki se pediatričnim bolnikom daptomicina ne sme dati z 2-minutno injekcijo.
Chemical and physical in-use stability on the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours if stored under refrigeration (2°C-8°C). 
Kemijsko in fizikalno stabilnost rekonstituirane raztopine v viali med uporabo so dokazali za 12 ur pri 25 °C in do 48 ur v primeru shranjevanja v hladilniku pri (2 °C - 8 °C).
In adults, daptomycin is given by intravenous infusion (see section 6.6) and administered over a 30-minute period or by intravenous injection (see section 6.6) and administered over a 2-minute period. 
Pri odraslih daptomicin dajemo v obliki 30-minutne intravenske infuzije (glejte poglavje 6.6) ali v obliki 2-minutne intravenske injekcije (glejte poglavje 6.6).
Gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension 
bolečine v prebavilih in trebuhu, navzea, bruhanje, zaprtje, diareja, flatulenca, napihnjenost trebuha občasni:
Tell your doctor or nurse straight away if you experience any of the following symptoms: - Chest pain or tightness, - Rash with blistering, sometimes affecting the mouth and genitals, - Swelling around throat, - Rapid or weak pulse, - Wheezing, - Fever, - Shivering or trembling, - Hot flushes, - Dizziness, - Fainting, - Metallic taste. 
Takoj obvestite zdravnika ali medicinsko sestro, če se vam pojavi katerikoli od naslednjih simptomov: - bolečina ali tiščanje v prsih;, - izpuščaj z mehurčki, ki včasih prizadene usta in spolovila, - otekanje okrog grla, - hiter ali šibek srčni utrip, - piskajoče dihanje, - zvišana telesna temperatura, - drgetanje ali tresenje, - vročinski oblivi, - omotica,
How to store Daptomycin Hospira 
Kako uporabljati zdravilo Daptomicin Hospira
Musculoskeletal and connective tissue disorders 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti:
To prepare Daptomycin Hospira for intravenous infusion, please adhere to the following instructions: Aseptic technique should be used throughout to reconstitute lyophilised Daptomycin Hospira. 
Pri pripravi zdravila Daptomicin Hospira za intravensko infuzijo upoštevajte naslednja navodila: Za rekonstitucijo liofiliziranega zdravila Daptomicin Hospira morate ves čas uporabljati aseptično tehniko.
Serious side effects with frequency not known (frequency cannot be estimated from the available data) A rare but potentially serious lung disorder called eosinophilic pneumonia has been reported in patients given daptomycin, mostly after more than 2 weeks of treatment. 
Pri bolnikih, ki so prejemali daptomicin, so poročali o redki, a potencialno resni pljučni bolezni, ki jo imenujemo eozinofilna pljučnica, ki se je večinoma pojavila po več kot 2 tednih zdravljenja.
Plasma exposures achieved with these doses were consistent with those achieved in the adult SAB study (following 6 mg/kg once daily in adults). 
Izpostavljenost v plazmi, dosežena s temi odmerki, je bila skladna z izpostavljenostjo, doseženo v študiji bakteriemije z bakterijo Staphylococcus aureus (po odmerku 6 mg/kg enkrat na dan pri odraslih).
Juvenile dogs developed peripheral and spinal nerve lesions at doses lower than those associated with skeletal muscle toxicity. 
Pri mladih psih so se pri odmerkih, ki so bili manjši od tistih, povezanih s toksičnostjo za skeletne mišice, pojavile lezije perifernih in spinalnih živcev.
Water should not be used for reconstitution of Daptomycin Hospira for intravenous injection. 
Za rekonstitucijo zdravila Daptomicin Hospira za intravensko injiciranje ne smete uporabiti vode.
(2) The same dose adjustments, which are based on PK data in volunteers including PK modelling results, are recommended for adult patients on haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). 
(2) Za odrasle bolnike na hemodializi (HD) ali kontinuirani ambulantni peritonealni dializi (CAPD) je priporočeno enako prilagajanje odmerka, ki temelji na farmakokinetičnih podatkih prostovoljcev, vključno z rezultati farmakokinetičnega modeliranja.
Uncommon: Thrombocythaemia, eosinophilia, international normalised ratio (INR) increased, leukocytosis 
trombocitemija, eozinofilija, povečanje mednarodno umerjenega razmerja (INR), levkocitoza redki:
Using a new syringe, insert the needle into the inverted vial. 
Vzemite novo injekcijsko brizgo in vstavite injekcijsko iglo v obrnjeno vialo.
Duration of Therapy 
Trajanje zdravljenja
Jaundice 
zlatenica
Tell a doctor or a nurse straight away if you experience symptoms suggestive of allergic reaction, such as wheezing, difficulty breathing, swelling of the face, neck and throat, rashes and hives, fever (see section 4 of this leaflet for more information). 
Če se pri vas pojavijo simptomi, ki kažejo na alergijsko reakcijo, na primer piskajoče dihanje, težko dihanje, otekanje obraza, vratu in žrela, izpuščaji in koprivnica, zvišana telesna temperatura, takoj obvestite zdravnika ali medicinsko sestro (za več informacij glejte poglavje 4 v tem navodilu za uporabo).
The pharmacokinetics of daptomycin were not significantly altered by aztreonam. 
Aztreonam ni bistveno spremenil farmakokinetičnih lastnosti daptomicina.
Transfer the reconstituted solution into a sodium chloride 9 mg/ml (0.9%) infusion bag (typical volume 50 ml). 
Rekonstituirano raztopino prenesite v infuzijsko vrečko z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida (običajni volumen 50 ml).
No clinical data on fertility are available for daptomycin. 
Za daptomicin ni na voljo nobenih kliničnih podatkov o vplivu na plodnost.
- The other ingredientsaresodium hydroxideand citric acid. 
- Drugi sestavini zdravila sta natrijev hidroksid in citronska kislina.
Although small changes in the pharmacokinetics of daptomycin and tobramycin were observed during coadministration by intravenous infusion over a 30-minute period using a daptomycin dose of 2 mg/kg, the changes were not statistically significant. 
Pri sočasnem dajanju daptomicina in tobramicina s 30-minutno intravensko infuzijo, kjer je bil odmerek daptomicina 2 mg/kg so opažali manjše spremembe v farmakokinetiki obeh zdravil, vendar spremembe niso bile statistično značilne.
In all populations the clinical success rates were comparable between the daptomycin and SOC treatment arms, supporting the primary efficacy analysis in the ITT population. 
V vseh populacijah je bila stopnja klinične uspešnosti v skupini z daptomicinom približno enaka kot v skupini s standardno oskrbo, kar se je ujemalo z rezultati primarne analize učinkovitosti v populaciji vseh bolnikov, predvidenih za zdravljenje (ITT-intent-to treat).
Daptomycin Hospira is administered intravenously in 0.9 % sodium chloride (see section 6.6). 
Zdravilo Daptomycin Hospira se daje v obliki intravenske infuzije v 0,9-odstotni raztopini natrijevega klorida (glejte poglavje 6.6).
After a single 4 mg/kg dose of daptomycin, total clearance normalised by weight and elimination half-life of daptomycin in adolescents (12-17 years of age) with Gram-positive infection were similar to adults. 
Po enkratnem odmerku 4 mg/kg daptomicina sta bila celotni očistek, normaliziran glede na telesno maso, in eliminacijski razpolovni čas daptomicina pri mladostnikih (starih od 12 do 17 let) z grampozitivnimi okužbami podobna kot pri odraslih.
However, some cases of marked rises in CPK levels and cases of rhabdomyolysis occurred in adult patients taking one of these medicinal products at the same time as daptomycin. 
Vendar pa je pri odraslih bolnikih, ki so jemali eno od teh zdravil sočasno z daptomicinom, v nekaj primerih prišlo do izrazitega zvišanja ravni CPK in primerov rabdomiolize.
Summary of overall therapeutic response by type of baseline pathogen (ME population): 
Povzetek skupnih terapevtskih izidov glede na vrsto osnovne okužbe (populacija za mikrobiološko oceno primernih bolnikov):
Failures with daptomycin in the treatment of enterococcal infections that were mostly accompanied by bacteraemia have been reported. 
Pri enterokoknih okužbah, ki jih je večinoma spremljala bakteriemija, so poročali o neuspehu zdravljenja z daptomicinom.
Staphylococcus haemolyticus 
Staphylococcus haemolyticus koagulazno negativni stafilokoki
350 mg presentation: 
Pakiranje po 350 mg:
Therefore, it is recommended that: - Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients. 
• Pri vseh bolnikih je treba raven CPK v plazmi izmeriti pred začetkom zdravljenja in nato v rednih intervalih (vsaj enkrat tedensko) med zdravljenjem.
No dose adjustment is necessary when administering daptomycin to patients with mild or moderate hepatic impairment (Child-Pugh Class B) (see section 5.2). 
Pri bolnikih z blago ali zmerno okvaro jeter (Child-Pugh B) prilagajanje odmerka daptomicina ni potrebno (glejte poglavje 5.2).
Anaphylaxis/hypersensitivity reactions have been reported with daptomycin. 
Pri uporabi daptomicina so poročali o anafilaktičnih/preobčutljivostnih reakcijah.
Drug/laboratory test interactions 
Vpliv zdravila na rezultate laboratorijskih preiskav
There is no clinical experience in patients with the administration of daptomycin as an injection over 2 minutes. 
Kliničnih izkušenj pri bolnikih, ki bi prejemali daptomicin v obliki injekcije v trajanju 2 minut, ni.
Chemical and physical stability of the diluted solution in infusion bags is established as 12 hours at 25°C or 24 hours at 2°C - 8°C. 
Razredčena raztopina v infuzijskih vrečkah je kemijsko in fizikalno stabilna 12 ur pri 25 °C ali 24 ur pri 2 °C - 8 °C.
Clostridium difficile-associated diarrhoea 
diareja, ki jo povzroča bakterija Clostridium difficile**
If this happens tell your doctor. 
Če se vam pojavijo taki simptomi, obvestite svojega zdravnika.
False prolongation of prothrombin time (PT) and elevation of international normalised ratio (INR) have been observed when certain recombinant thromboplastin reagents are utilised for the assay (see section 
Pri uporabi določenih rekombinantnih tromboplastinskih reagentov za določanje protrombinskega časa so opažali lažno podaljšanje protrombinskega časa (PČ) in zvišanje vrednosti mednarodno umerjenega razmerja (INR - International Normalised Ratio) (glejte poglavje 4.5).
In all populations the clinical success rates were comparable in the daptomycin versus the SOC treatment arm. 
V vseh populacijah so bili deleži kliničnega uspeha med skupino z daptomicinom in skupino s standardno oskrbo primerljivi.
Comparator n/N (%) 
Primerjalno zdravilo n/N (%)
AUC0-24hr (g×hr/ml) Cmax (g/ml) Apparent t1/2 (hr) CL/wt (ml/hr/kg) Pharmacokinetic parameter values estimated by noncompartmental analysis Individual values reported as only two patients in this age group provided pharmacokinetic samples to enable pharmacokinetic analysis; AUC, apparent t1/2 and CL/wt could be determined for only one of the two patients Pharmacokinetic analysis conducted on the pooled pharmacokinetic profile with mean concentrations across subjects at each time point 
Navedeni sta posamezni vrednosti, ker so le od dveh bolnikov v tej starostni skupini pridobili farmakokinetične vzorce, ki so omogočali farmakokinetično analizo; AUC, navidezni t1/2 in očistek na telesno maso so lahko določili le pri enem od teh dveh bolnikov.
Renal impairment has been reported during treatment with daptomycin. 
Med zdravljenjem z daptomicinom so poročali o okvari ledvic.
500 mg presentation: 
Pakiranje po 500 mg:
Table 2 Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric cSSTI Patients (1 to 17 Years of Age) in Study DAP-PEDS-07-03 
Preglednica 2 Povprečje (standardni odklon) farmakokinetike daptomicina pri pediatričnih bolnikih (starih od 1 do 17 let) z zapletenimi okužbami kože in mehkih tkiv v študiji DAP-PEDS-07-03 Razpon starosti
Comparable exposure (AUC and Cmax) was demonstrated in healthy adult subjects following administration of daptomycin as a 30-minute intravenous infusion or as a 2-minute intravenous injection. 
Pri zdravih odraslih preskušancih so po uporabi daptomicina v obliki 30-minutne intravenske infuzije ali 2-minutne intravenske injekcije opazili primerljivo izpostavljenost zdravilu (AUC in Cmax).
Skin and subcutaneous tissue disorders 
Zapletene okužbe kože in mehkih tkiv (cSSTI) brez SAB
Table 3 Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric SAB Patients (1 to 17 Years of Age) in Study DAP-PEDBAC-11-02 
Preglednica 3 Povprečje (standardni odklon) farmakokinetike daptomicina pri pediatričnih bolnikih (starih od 1 do 17 let) z bakteriemijo z bakterijo Staphylococcus aureus v študiji DAP-PEDBAC-11-02 Razpon starosti
Fungal infections, urinary tract infection, candida infection, anaemia, anxiety, insomnia, dizziness, headache, hypertension, hypotension, gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension, liver function tests abnormal (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)), rash, pruritus, limb pain, serum creatine phosphokinase (CPK) increased, infusion site reactions, pyrexia, asthenia. 
Neželeni učinki, o katerih so najpogosteje poročali (s pogostnostjo "pogosti" (≥ 1/100 do < 1/10)), so: glivične okužbe, okužbe sečil, okužba s kandido, anemija, tesnoba, nespečnost, omotica, glavobol, hipertenzija, hipotenzija, bolečine v prebavilih in trebuhu, navzea, bruhanje, zaprtje, diareja, flatulenca, napihnjenost trebuha, nenormalni izvidi preiskav delovanja jeter (zvišane vrednosti alaninaminotransferaze (ALT), aspartat-aminotransferaze (AST) ali alkalne fosfataze (ALP)), izpuščaj, pruritis, bolečine v okončinah, zvišane vrednosti kreatin-fosfokinaze (CPK) v serumu, reakcije na mestu infundiranja, zvišana telesna temperatura, astenija.
Safety margins for peripheral nerve effects in rats and dogs are 8- and 6-fold, respectively, based on comparison of Cmax values at the No Observed Effect Level (NOEL) with the Cmax achieved on dosing with 30-minute intravenous infusion of 6 mg/kg once daily in patients with normal renal function. 
Glede na primerjavo vrednosti Cmax pri odmerku brez opaznega učinka (NOEL - No Observed Effect Level) in vrednosti Cmax pri odmerjanju 6 mg/kg enkrat dnevno s 30-minutno intravensko infuzijo pri bolnikih z normalnim delovanjem ledvic je varno območje za učinke na periferne živce pri podganah in psih 8-kratna oziroma 6-kratna vrednost.
Common: may affect up to 1 in 10 people - Fungal infections such as thrush, - Urinary tract infection, - Decreased number of red blood cells (anaemia), - Dizziness, anxiety, difficulty in sleeping, - Headache, - Fever, weakness (asthenia), - High or low blood pressure, - Constipation, abdominal pain, - Diarrhoea, feeling sick (nausea) or being sick (vomiting), - Flatulence, - Abdominal swelling or bloating, - Skin rash or itching, - Pain, itchiness or redness at the site of infusion, - Pain in arms or legs, - Blood testing showing higher levels of liver enzymes or creatine phosphokinase (CPK). 
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov - glivične okužbe, kot je kandidoza - okužba sečil - zmanjšano število rdečih krvnih celic (anemija) - omotica, tesnoba, težave s spanjem - glavobol - zvišana telesna temperatura, oslabelost (astenija) - visok ali nizek krvni tlak - zaprtje, bolečine v trebuhu - driska, slabost s siljenjem na bruhanje (navzea) ali bruhanje - nabiranje plinov v želodcu ali črevesju - otekanje ali napihnjenost trebuha - kožni izpuščaj ali srbenje kože - bolečina, srbenje ali rdečina na mestu infundiranja - bolečine v rokah ali nogah - izvidi krvnih preiskav, ki kažejo zvišane vrednosti jetrnih encimov ali kreatin-fosfokinaze (CPK)
5 mg/kg 30 minutes 
5 mg/kg 30 minut
Daptomycin Hospira 350 mg powder for solution for injection/infusion Daptomycin Hospira 500 mg powder for solution for injection/infusion 
Daptomicin Hospira 350 mg prašek za raztopino za injiciranje/infundiranje Daptomicin Hospira 500 mg prašek za raztopino za injiciranje/infundiranje
AUC0-24hr (g×hr/ml) Cmax (g/ml) Apparent t1/2 (hr) CL/wt (ml/hr/kg) Pharmacokinetic parameter values estimated using a model-based approach with sparsely collected pharmacokinetic samples from individual patients in the study. 
(ml/h/kg) Vrednosti farmakokinetičnih parametrov, ocenjene na podlagi modela z redkim farmakokinetičnim vzorčenjem pri posameznih bolnikih v študiji.
Microbiological Success rate in Paedatric SAB n/N (%) 
Mikrobiološki delež uspeha pri pediatričnih bolnikih z bakteriemijo z bakterijo Staphylococcus aureus n/N (%)
Daptomycin Hospira 350 mg powder for solution for injection/infusion Each vial contains 350 mg daptomycin. 
Daptomicin Hospira 350 mg prašek za raztopino za injiciranje/infundiranje Ena viala vsebuje 350 mg daptomicina.
Caution is warranted when daptomycin is co-administered with tobramycin. 
Pri sočasni uporabi daptomicin s tobramicinom je potrebna previdnost.
Following administration of a single 4 mg/kg intravenous dose of daptomycin over a 30-minute period, the mean total clearance of daptomycin was approximately 35% lower and the mean AUC0-∞ was approximately 58% higher in elderly subjects (≥ 75 years of age) compared with those in healthy young subjects (18 to 30 years of age). 
Po 30-minutnem dajanju daptomicina v enkratnem intravenskem odmerku 4 mg/kg je bila pri starejših osebah (starih ≥ 75 let) povprečna vrednost celotnega očistka daptomicina nižja za približno 35 %,
The safety and efficacy of daptomycin was evaluated in paediatric patients aged 1 to 17 years (Study DAP-PEDS-07-03) with cSSTI caused by Gram positive pathogens. 
Varnost in učinkovitost daptomicina so ocenjevali pri pediatričnih bolnikih, ki so bili stari od 1 do 17 let in so imeli zapleteno okužbo kože in mehkih tkiv s katerim od grampozitivnih patogenov (študija DAP-PEDS-07-03).